The CDNR Platform – Progressing the Promise of Personalized Medicine

CDNR Novaseek Research Science Exchange

Most everyone knows that precision medicine promises to transform the healthcare landscape, delivering powerful and personalized treatments for previously intractable diseases. Even so, biotech innovators still face tremendous hurdles in realizing this promise — chief among them, finding access to sufficient numbers of annotated, characterized and consented patient samples. Novaseek Research has developed a unique […]

Read More…

Science Exchange Announces Outsourced R&D Partnership with Alector

partnership

  PALO ALTO, Calif.–Science Exchange, the world’s leading and most secure enterprise platform and aggregator for outsourced research and development (R&D), today announced a strategic partnership with Alector, a biotech company pioneering the discovery & development of immuno-neurology therapies for neurodegenerative disorders, to provide the company’s scientists access to a private R&D marketplace to accelerate […]

Read More…

QB3 Signs Partnership with Science Exchange

partnership

Bay Area Life Science Hub Enables its Startups to Stay Lean with Science Exchange’s R&D Platform PALO ALTO, CA, October 23, 2017 – Science Exchange, a platform for outsourced research and development (R&D) services, today announced a partnership with QB3, the University of California hub for innovation and entrepreneurship for life sciences. Through an exclusive […]

Read More…

Science Exchange Raises $28M in Series C Funding

fundraising

Funding led by Norwest Venture Partners with participation from Union Square Ventures, Maverick Capital and Collaborative Fund Palo Alto, CA – June 29, 2017 – As further evidence of its position as the world’s leading platform for outsourced research and development (R&D), Science Exchange today announced it has raised $28 million in Series C funding. Founded in […]

Read More…

Science Exchange Stories: Pat Corsino from Nuovo Biologics

antiviral

Our user Pat Corsino, a R&D Manager at Nuovo Biologics, is studying the mechanism of action behind their antiviral and oncology technologies. I spoke with him about life and efficiency at an early-stage biotech, check out his advice about being proactive at a small biotech! Q: What does Nuovo Biologics do? Pat: We’re a small […]

Read More…

Science Exchange Stories: OncoSynergy, fighting brain cancer as the family business

brain-cancer

This week I got to catch up with our user Shawn Carbonell and his biotech company OncoSynergy, who has made exciting progress in the 2 months since we last talked. They were honored with the Children’s Humanitarian Award from the Children’s Tumor Foundation at their annual Gala in New York City and have just announced […]

Read More…

Small Biotech Stories: Eos Neuroscience

neuroscience

Eos Neuroscience is a company built on collaboration, featuring a unique team with expertise in transgenes, virology and gene expression, and retinal degeneration. Once they complete their preclinical stage, their intended userbase would be those with blindness attributed to photoreceptor degeneration, or age-related macular degeneration. They are running into some problems in the process of […]

Read More…

Science Exchange Stories: Shawn Carbonell, Brain Surgery Dropout

monoclonal-antibody

Have you ever had a big idea that burned a hole in your brain? Plagued you day after day? Well, that’s exactly what happened to Shawn Carbonell, the CEO and Chief Scientific Officer of OncoSynergy. Although he had spent the last 18 years prepping for a career as an academic neurosurgeon, he couldn’t stop thinking […]

Read More…

Small Biotech Stories: American CryoStem

Some companies skirt regulations, opting instead to go off the radar. American CryoStem‘s Anthony Dudzinski‘s first words to me on the phone during our discussion were, “We follow the rules.” They’ve accumulated the greatest depth of adipose tissue-based cellular technology research relative to creating their laboratory and processes at a clinical cGMP level, and they’ve […]

Read More…